Non-cirrhotic metabolic dysfunctionassociated steatohepatitis (MASH) with moderate to advanced liver fibrosis maintenance dose: 2.4 mg injected once weekly
Mercier, MD Kimberli Hastings, NP Family Nurse Practitioner Family Medicine and Mental Health practitioner dedicated to collaborative, patient-centered care
Understanding how these medications affect the digestive system is essential for both clinicians and patients, as it provides context for managing potential side effects while maximizing therapeutic benefits for diabetes control and weight management
Mori Y, Matsui T, Hirano T, Yamagishi SI
On tolerability, retatrutide's GI adverse event rate is higher than tirzepatide's at matched mechanistic dose, which is the tradeoff for the additional mechanism
Its allure stems from its ability to help people lose significant amounts of weight